On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Sage Therapeutics Stock A Buy?
Sage Therapeutics stock is trying to complete a cup with handle with a 43.70 buy point. See if the stock can clear the breakout price in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
In terms of top and bottom line numbers, the company has posted rising EPS growth in each of the last two reports. Sales growth has been less impressive, coming in at -9% in the latest report.
Sage Therapeutics stock earns the No. 170 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Genmab and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
